- There’s no shortage of market-moving news these days about up-and-coming cancer drug maker I-Mab, whose stock is getting pulled every which way as a result.
- The U.S.-China dispute element was in the headlines this week, when I-Mab’s name was added to a U.S. Securities and Exchange Commission list of 88 Chinese firms that could face potential delisting.
- According to its 2021 annual report, the company has enough capital to fund its operations through 2025, with $671 million in cash combined with expected milestone payments.
For further details see:
I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat